Send to

Choose Destination
Cancer Cell. 2012 Nov 13;22(5):569-70. doi: 10.1016/j.ccr.2012.10.016.

Epigenetic therapy leaps ahead with specific targeting of EZH2.

Author information

Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA.


The Polycomb epigenetic silencing protein EZH2 is affected by gain-of-function somatic mutations in B cell lymphomas. Two recent reports describe the development of highly selective EZH2 inhibitors and reveal mutant EZH2 as playing an essential role in maintaining lymphoma proliferation. EZH2 inhibitors are thus a promising new targeted therapy for lymphoma.

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center